TherapeuticsMD Q2 EPS $(0.09) Up From $(0.24) YoY, Sales $234.00K Down From $437.00K YoY
Portfolio Pulse from Benzinga Newsdesk
TherapeuticsMD (NASDAQ:TXMD) reported Q2 earnings per share (EPS) of $(0.09), an improvement from $(0.24) YoY. However, sales decreased by 46.45% to $234,000 from $437,000 YoY.
August 12, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TherapeuticsMD reported improved EPS of $(0.09) for Q2, up from $(0.24) YoY, but sales fell by 46.45% to $234,000. The mixed results may lead to short-term volatility in the stock price.
The improvement in EPS is a positive sign, but the significant drop in sales is concerning. Investors may react with mixed sentiments, leading to short-term volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100